Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvoxamine SCHEMBL5569574 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL341698 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL178609 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL8674929 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5960517 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL27816994 | 0.98 | SLC6A4 (0.95) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13090665 | 0.96 | SLC6A4 (0.93) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5508120 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL30628144 | 0.92 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17702850 | 0.91 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35249 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026102521-A1 | USE OF A PURINE COMPOUND FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MARVEL BIOTECHNOLOGY (CA) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-5223540-A | Fluvoxamine | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-06-29 | — | — | US | claimed |
| US-5179126-A | Compositions for treating tobacco withdrawl symtoms and methods for their use | MASSACHUSETTES INSTITUTE OF TECHNOLOGY (US) | 1993-01-12 | — | — | US | claimed |
| WO-1992018005-A1 | METHOD OF TREATING TRICHOTILLOMANIA AND ONYCHOPHAGIA | NATIONAL INSTITUTES OF HEALTH (US) | 1992-10-29 | — | — | WO | claimed |
| WO-1992000103-A1 | PHARMACEUTICAL PREPARATIONS | BEECHAM GROUP PLC (GB) | 1992-01-09 | — | — | WO | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0293714-B1 | COMBINATIONS OF COMPOUNDS WITH ANTI-DEPRESSIVE ACTIVITY | Troponwerke GmbH & Co. KG (DE) | 1991-06-05 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| US-4956361-A | DICARBOXYLIC ACID ESTERS OF DIHYDROPYRIDINES | TROPONWERKE GMBH & CO. KG (DE) | 1990-09-11 | — | — | US | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |